Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2021

21.10.2021 | ASCO 2021 | short review

Ovarian cancer—ASCO annual meeting update 2021

verfasst von: Johannes Schöche, Kathrin Strasser-Weippl

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The 2021 ASCO annual meeting did not change clinical practice in the treatment of ovarian cancer, but several interesting studies were presented that might have clinical impact in the future. One phase III study, by demonstrating no improved overall survival for an extended maintenance duration of bevacizumab treatment, supports the current standard of care of 15 months of bevacizumab for first-line maintenance. Data on Poly(ADP-ribose)-polymerase inhibitors (PARP inhibitors) again confirmed their marked clinical benefit, most prominently in certain biomarker subpopulations. Finally, new drug candidates with promising clinical activity include agents targeting ATR, Wee1, and folate receptor alpha.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Fußnoten
1
In the following, under the term “advanced ovarian cancer”, the entities epithelial ovarian, fallopian tube, and primary peritoneal cancer in International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C, and IV will be subsumed.
 
2
Notably, the CBR was defined as stable disease for at least four cycles (or complete and partial remission). Attributing clinical benefit after only four cycles is arguably early—this should be considered when interpreting the study results.
 
Literatur
3.
Zurück zum Zitat Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, et al. Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2‑arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). Journal of Clinical Oncology [Internet]. 2021 May 20 [cited 2021 Jun 27];39(15_suppl):5501–5501. Available from: https://​ascopubs.​org/​doi/​10.​1200/​JCO.​2021.​39.​15_​suppl.​5501 Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, et al. Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2‑arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). Journal of Clinical Oncology [Internet]. 2021 May 20 [cited 2021 Jun 27];39(15_suppl):5501–5501. Available from: https://​ascopubs.​org/​doi/​10.​1200/​JCO.​2021.​39.​15_​suppl.​5501
4.
Zurück zum Zitat Moore K, Colombo N, Scambia G, Kim B‑G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;27;379(26):2495–505. Dec. CrossRef Moore K, Colombo N, Scambia G, Kim B‑G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;27;379(26):2495–505. Dec. CrossRef
6.
Zurück zum Zitat Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;19;381(25):2416–28. Dec. CrossRef Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;19;381(25):2416–28. Dec. CrossRef
10.
Zurück zum Zitat Mirza MR, Åvall Lundqvist E, Birrer MJ. dePont Christensen R, Nyvang GB, Malander S, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;1;20(10):1409–19. Oct. CrossRef Mirza MR, Åvall Lundqvist E, Birrer MJ. dePont Christensen R, Nyvang GB, Malander S, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;1;20(10):1409–19. Oct. CrossRef
14.
Zurück zum Zitat Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Molecular Cancer Therapeutics [Internet]. 2009 Nov [cited 2021 Jun 27];8(11):2992–3000. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​19887545/​ Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Molecular Cancer Therapeutics [Internet]. 2009 Nov [cited 2021 Jun 27];8(11):2992–3000. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​19887545/​
15.
Zurück zum Zitat Leijen S, van Geel RMJM, Pavlick AC, Tibes R, Rosen L, Razak ARA, et al. Phase I study evaluating WEE1 inhibitor AZD1775as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology [Internet]. 2016 Dec 20 [cited 2021 Jun 27];34(36):4371–80. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​27601554/​ Leijen S, van Geel RMJM, Pavlick AC, Tibes R, Rosen L, Razak ARA, et al. Phase I study evaluating WEE1 inhibitor AZD1775as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. Journal of Clinical Oncology [Internet]. 2016 Dec 20 [cited 2021 Jun 27];34(36):4371–80. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​27601554/​
16.
Zurück zum Zitat Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, et al. Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors. Journal of Clinical Oncology [Internet]. 2015 Oct 20 [cited 2021 Jun 27];33(30):3409–15. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​25964244/​ Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, et al. Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors. Journal of Clinical Oncology [Internet]. 2015 Oct 20 [cited 2021 Jun 27];33(30):3409–15. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​25964244/​
18.
Zurück zum Zitat Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology [Internet]. 2021 Jun 1 [cited 2021 Jun 27];32(6):757–65. Available from: https://​doi.​org/​10.​1016/​j.​annonc.​2021.​02.​017 Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology [Internet]. 2021 Jun 1 [cited 2021 Jun 27];32(6):757–65. Available from: https://​doi.​org/​10.​1016/​j.​annonc.​2021.​02.​017
19.
Zurück zum Zitat Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia (United States). 2016 Dec 1;18(12):775–84. Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia (United States). 2016 Dec 1;18(12):775–84.
21.
Zurück zum Zitat O’Malley DM, Oaknin A, Matulonis UA, Mantia-Smaldone G, Lim PC, Castro CM, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. Journal of Clinical Oncology [Internet]. 2021 May 20 [cited 2021 Jun 27];39(15_suppl):5504–5504. Available from: https://​ascopubs.​org/​doi/​10.​1200/​JCO.​2021.​39.​15_​suppl.​5504 O’Malley DM, Oaknin A, Matulonis UA, Mantia-Smaldone G, Lim PC, Castro CM, et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. Journal of Clinical Oncology [Internet]. 2021 May 20 [cited 2021 Jun 27];39(15_suppl):5504–5504. Available from: https://​ascopubs.​org/​doi/​10.​1200/​JCO.​2021.​39.​15_​suppl.​5504
22.
23.
Zurück zum Zitat Pilié PG, Tang C, Mills GB, Yap TA. Nature Reviews Clinical Oncology. Nature Publishing Group. State-of-the-art strategies for targeting the DNA damage response in cancer, Vol. 16. 2019. pp. 81–104. Pilié PG, Tang C, Mills GB, Yap TA. Nature Reviews Clinical Oncology. Nature Publishing Group. State-of-the-art strategies for targeting the DNA damage response in cancer, Vol. 16. 2019. pp. 81–104.
24.
Zurück zum Zitat Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;1;16(2):110–20. Feb. CrossRef Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;1;16(2):110–20. Feb. CrossRef
25.
Zurück zum Zitat O’Connor MJ. Targeting the DNA Damage Response in Cancer. Vol. 60, Molecular Cell. Cell Press; 2015. p. 547–60. O’Connor MJ. Targeting the DNA Damage Response in Cancer. Vol. 60, Molecular Cell. Cell Press; 2015. p. 547–60.
26.
Zurück zum Zitat Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic [Internet]. Vol. 355, Science. American Association for the Advancement of Science; 2017 [cited 2020 Sep 14]. p. 1152–8. Available from: /pmc/articles/PMC6175050/?report=abstract Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic [Internet]. Vol. 355, Science. American Association for the Advancement of Science; 2017 [cited 2020 Sep 14]. p. 1152–8. Available from: /pmc/articles/PMC6175050/?report=abstract
27.
Zurück zum Zitat Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. Vol. 110, Journal of the National Cancer Institute. Oxford University Press; 2018. p. 704–13. Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. Vol. 110, Journal of the National Cancer Institute. Oxford University Press; 2018. p. 704–13.
28.
Zurück zum Zitat Watkins JA, Irshad S, Grigoriadis A, Tutt ANJ. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers [Internet]. Vol. 16, Breast Cancer Research. BioMed Central Ltd.; 2014 [cited 2021 Jul 3]. p. 211. Available from: /pmc/articles/PMC4053155/ Watkins JA, Irshad S, Grigoriadis A, Tutt ANJ. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers [Internet]. Vol. 16, Breast Cancer Research. BioMed Central Ltd.; 2014 [cited 2021 Jul 3]. p. 211. Available from: /pmc/articles/PMC4053155/
30.
Zurück zum Zitat Blanc-Durand F, Yaniz E, Genestie C, Rouleau E, Berton D, Lortholary A, et al. Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. J Clin Oncol. 2021;20;39(15_suppl):5513–5513. May. CrossRef Blanc-Durand F, Yaniz E, Genestie C, Rouleau E, Berton D, Lortholary A, et al. Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. J Clin Oncol. 2021;20;39(15_suppl):5513–5513. May. CrossRef
31.
Zurück zum Zitat Ferron G, de Rauglaudre G, Chevalier A, Combe P, Joly F, Lortholary A, et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study. J Clin Oncol. 2019;20;37(15_suppl):5512–5512. May. CrossRef Ferron G, de Rauglaudre G, Chevalier A, Combe P, Joly F, Lortholary A, et al. Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study. J Clin Oncol. 2019;20;37(15_suppl):5512–5512. May. CrossRef
Metadaten
Titel
Ovarian cancer—ASCO annual meeting update 2021
verfasst von
Johannes Schöche
Kathrin Strasser-Weippl
Publikationsdatum
21.10.2021
Verlag
Springer Vienna
Schlagwort
ASCO 2021
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00772-8